Abstract:Structural classification and regulatory functions of histone deacetylases and their inhibitors. Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Targeting histone deacetylases: Emerging applications beyond cancer

Targeting histone deacetylases for heart diseases

Targeting histone deacetylase in cardiac diseases

Targeting histone deacetylases for cancer therapy: Trends and challenges

Role of histone deacetylases and their inhibitors in neurological diseases

New Development of HDAC Inhibitors As Anti-Cancer Agents

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

Advances in targeting histone deacetylase for treatment of solid tumors

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

Therapeutic application of histone deacetylase inhibitors for stroke.

Histone deacetylases: Regulation of vascular homeostasis via endothelial cells and vascular smooth muscle cells and the role in vascular pathogenesis

Histone Deacetylases (HDACs) Roles in Inflammation-mediated Diseases; Current Knowledge

HDACi: molecular mechanisms and therapeutic implications in the innate immune system